CClinicalTrials.gg
CompletedNCT04601259Updated Sep 9, 2021

A Clinical Investigation to Evaluate The Orkla Corn Plaster

An interventional study of Orkla Corn Plaster with salicylic acid and Orkla Corn Protector in Corns, sponsored by Orkla Care AB. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-09.

Sponsored by Orkla Care AB · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, randomized, controlled, open-labelled investigation to assess performance and safety of Orkla Corn Plaster in subject with corns. The hypothesis is that there is an improvement in the size of corns at day 28 compared to baseline.

02

Conditions studied

  • Corns
03

In context

Lead sponsor

This is the only study on the registry with Orkla Care AB as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Signed Informed Consent Form
  2. >18 years of age
  3. Presence of corn(s) confirmed by Investigator
  4. Corn included into investigation shall not have been subject to any other treatment 1 month prior to study enrolment.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women at time of enrolment
  2. Subjects with hypersensitivity to salicylic acid/salicylates, polyethylene foil, acrylic adhesive, viscose/polyethylene fibers and azorubine
  3. Subjects diagnosed with diabetes
  4. Subjects with poor peripheral blood circulation
  5. Subjects with renal dysfunction (eGFR \<60 mL/min/1.73 m2)
  6. Subjects with ongoing skin disease in the area where the index corn is located.
  7. Subjects with any other condition that as judged by the investigator may make follow-up or investigations procedures inappropriate
  8. Any subject that according to the Declaration of Helsinki is unsuitable for enrollment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Orkla corn plaster with Salicylic acid

    Combination Product: Orkla Corn Plaster with salicylic acid

  • Active comparator
    Orkla corn protector without salicylic acid

    Device: Orkla Corn Protector

Interventions

  • Combination productOrkla Corn Plaster with salicylic acid

    Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.

  • DeviceOrkla Corn Protector

    Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.

06

What researchers measure

Primary outcomes

  1. Percentage of improved subjects treated with Orkla Corn Plaster (with salicylic acid) at D28 compared to D0 (baseline)

    Time frame: 28 days

Secondary outcomes

  1. Difference in percentage of improved subjects from D0 (baseline) to D28 between Orkla Corn Plaster (with salicylic acid) and Orkla Corn Protector (without salicylic acid)

    Time frame: 28 days

  2. Percentage of improved subjects at D14, 3 and 6 months compared to baseline.

    Comparisons within the Orkla Corn Plaster group, and comparison between the two treatment groups Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 14 days, 3 months and 6 months

  3. Pain experienced from index corn recorded on Visual Analog Scale (VAS; scale: 0-100 mm where a higher score corresponds to worse pain) at D14, D28, 3 and 6 months compared to baseline.

    Comparisons within the Orkla Corn Plaster group, and comparison between the two treatment groups Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 14 days, 28 days, 3 months and 6 months

  4. Pain assessment recorded on Visual Analog Scale (VAS; scale: 0-100 mm where a higher score corresponds to worse pain) before and immediately after plaster application

    Comparisons within the Orkla Corn Plaster group, and comparison between the two treatment groups Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: Before and immediately after plaster application

  5. Resolution of corn at D14, D28, 3 and 6 months

    Comparisons within the Orkla Corn Plaster group, and comparison between the two treatment groups Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 14 days, 28 days, 3 months and 6 months

  6. Subject reported resolution point of time (diary)

    Comparisons within the Orkla Corn Plaster group, and comparison between the two treatment groups Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: Up to 6 months

  7. Percentage of subjects with recurrence at D14, D28, 3 and 6 months

    Comparisons within the Orkla Corn Plaster group, and comparison between the two treatment groups Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 14 days, 28 days, 3 months and 6 months

  8. Corn size reduction (mm) at D14, D28, 3 and 6 months

    Comparisons within the Orkla Corn Plaster group, and comparison between the two treatment groups Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 14 days, 28 days, 3 months and 6 months

  9. Usability questionnaire: Ease of application assessed via subject-reported question with a 5-point qualitative scale.

    Percentage of subjects selecting a given answer is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 14 days, 28 days

  10. Usability questionnaire: Adherence to the application site assessed via subject-reported question with a 5-point qualitative scale.

    Percentage of subjects selecting a given answer is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 14 days, 28 days

  11. Subject treatment satisfaction questionnaire: Overall treatment satisfaction assessed via subject-reported question with a 5-point qualitative scale

    Percentage of subjects selecting a given answer is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 28 days

  12. Subject treatment satisfaction questionnaire: Corn appearance improvement assessed via subject-reported question with a 5-point qualitative scale

    Percentage of subjects selecting a given answer is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 28 days

  13. Subject treatment satisfaction questionnaire: Product recommendation assessed via subject-reported question with answer alternatives Yes/No/Don't know

    Percentage of subjects selecting a given answer is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 28 days

  14. Investigator treatment satisfaction questionnaire: Overall treatment satisfaction assessed via investigator-reported question with a 5-point qualitative scale

    Percentage of subjects for each answer alternative (judged by investigator) is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 28 days

  15. Investigator treatment satisfaction questionnaire: Corn appearance improvement assessed via investigator-reported questionnaire with a 5-point qualitative scale

    Percentage of subjects for each answer alternative (judged by investigator) is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 28 days

  16. Investigator treatment satisfaction questionnaire: Product recommendation assessed via investigator-reported questionnaire with answer alternatives Yes/No/Don't know

    Percentage of subjects for each answer alternative (judged by investigator) is presented with comparisons within the Orkla Corn Plaster group, and comparisons between the two treatment groups, Orkla Corn Plaster vs. Orkla Corn Protector.

    Time frame: 28 days

Other outcomes

  1. Incidence of adverse events (AE), adverse device effects (ADE), serious adverse events (SAE), and serious adverse device effects (SADE), and device deficiency (DD) throughout the clinical investigation.

    Time frame: 6 months

07

Study locations

1 site
  • Carlanderska Hospital
    Gothenburg, 405 45, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04601259
Lead sponsor
Orkla Care AB
Responsible party
Sponsor
First posted
Oct 23, 2020
Start date
Oct 21, 2020
Primary completion
Jan 14, 2021
Completion
Jun 10, 2021
Last update
Sep 9, 2021

Study contacts

Felix Lundin
principal investigator · Carlanderska Hospital, Carlandersparken 1, 405 45 Göteborg, Sweden.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion